title: P-glycoprotein modulation by the designer drugs methylenedioxymethamphetamine, methylenedioxyethylamphetamine and paramethoxyamphetamine.
abstract: There are increasing numbers of deaths related to taking MDMA, MDE and PMA reported where the deceased typically took several different drugs with these compounds. Hence, mutual modulation of the pharmacokinetics in drug combinations with "ecstasy" might be a risk factor for "ecstasy"-related morbidity. Regarding potential drug - drug interactions, there are no data evaluating a possible contribution of the multidrug resistance transporter P-glycoprotein (Pgp) in contrast to the cytochrome P450 enzyme system. Therefore, individual "ecstasy" compounds have been tested for their ability to interact with Pgp using a fluorometric calcein assay as a model for Pgp inhibition in porcine kidney epithelial cells with overexpression of human Pgp (L-MDR1). All three compounds increased calcein retention in L-MDR1 cells in a concentration-dependent manner, with MDE being the most potent and MDMA the weakest Pgp inhibitor. The effective concentrations were 1 - 3 orders of magnitude higher than plasma concentrations observed in vivo, suggesting that these compounds are only weak inhibitors of Pgp, which is unlikely to influence the access of other compounds to the brain. However, it cannot be excluded that co-administration of Pgp inhibitors such as ritonavir or paroxetine could increase MDMA, MDE and PMA bioavailability and also enhance brain entry leading to severe side effects.
authors.affiliation: Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University Hospital, Bergheimer Strasse 58, D-69115 Heidelberg, Germany.
authors.forename: Nahal
authors.initials: N
authors.lastname: Ketabi-Kiyanvash
authors.forename: Johanna
authors.initials: J
authors.lastname: Weiss
authors.forename: Walter Emil
authors.initials: WE
authors.lastname: Haefeli
authors.forename: Gerd
authors.initials: G
authors.lastname: Mikus
mesh_terms: D015104:3,4-Methylenedioxyamphetamine / Q000493:pharmacokinetics / Q000633:toxicity*; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000037:antagonists & inhibitors*; D019969:Amphetamine-Related Disorders / Q000097:blood*; D000662:Amphetamines / Q000493:pharmacokinetics / Q000633:toxicity*; D000818:Animals; D001682:Biological Availability; D015198:Designer Drugs / Q000493:pharmacokinetics / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005452:Fluoresceins / Q000378:metabolism; D005470:Fluorometry; D015870:Gene Expression / Q000187:drug effects; D019450:Genes, MDR / Q000235:genetics; D006801:Humans; D018374:LLC-PK1 Cells; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000493:pharmacokinetics / Q000633:toxicity*; D013552:Swine; D014162:Transfection
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000662:Amphetamines; D015198:Designer Drugs; D005452:Fluoresceins; C085925:calcein AM; D015104:3,4-Methylenedioxyamphetamine; D018817:N-Methyl-3,4-methylenedioxyamphetamine; C100230:4-methoxyamphetamine